参考文献:
[1]BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2]CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[3]KUDO M, IZUMI N, ICHIDA T, et al. Report of the 19th follow-up survey of primary liver cancer in Japan[J]. Hepatol Res, 2016, 46(5): 372-390.
[4]DONG LQ, PENG LH, MA LJ, et al. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma[J]. J Hepatol, 2020, 72(5): 896-908.
[5]XIE DY, FAN HK, REN ZG, et al. Identifying clonal origin of multifocal hepatocellular carcinoma and its clinical implications[J]. Clin Transl Gastroenterol, 2019, 10(2): e00006.
[6]RAMACCIATO G, MERCANTINI P, PETRUCCIANI N, et al. Does surgical resection have a role in the treatment of large or multinodular hepatocellular carcinoma?[J]. Am Surg, 2010, 76(11): 1189-1197.
[7]BRUIX J, REIG M, SHERMAN M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma[J]. Gastroenterology, 2016, 150(4): 835-853.
[8]BRUIX J, TAKAYAMA T, MAZZAFERRO V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): A phase 3, randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2015, 16(13): 1344-1354.
[9]WHITE R, NAIR RL, BRADLEY RH. Theorizing the benefits and costs of adaptive cultures for development[J]. Am Psychol, 2018, 73(6): 727-739.
[10]KUDO M, FINN RS, QIN S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173.
[11]SPINZI G, PAGGI S. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(23): 2497-2498; author reply 2498-2499.
[12]CROCENZI TS, EL-KHOUEIRY AB, YAU TC, et al. Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study [J]. 2017, 35(15 suppl): 4013.
[13]EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502.
[14]ZHU AX, FINN RS, EDELINE J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7): 940-952.
[15]KELLEY RK. Adjuvant sorafenib for liver cancer: Wrong stage, wrong dose[J]. Lancet Oncol, 2015, 16(13): 1279-1281.
[16]HUANG A, ZHAO X, YANG XR, et al. Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma[J]. J Hepatol, 2017, 67(2): 293-301.
[17]LIN DC, MAYAKONDA A, DINH HQ, et al. Genomic and epigenomic heterogeneity of hepatocellular carcinoma[J]. Cancer Res, 2017, 77(9): 2255-2265.
[18]TORRECILLA S, SIA D, HARRINGTON AN, et al. Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma[J]. J Hepatol, 2017, 67(6): 1222-1231.
[19]FEO F, PASCALE RM. Multifocal hepatocellular carcinoma: Intrahepatic metastasis or multicentric carcinogenesis?[J]. Ann Transl Med, 2015, 3(1): 4.
[20]GAO Q, WANG ZC, DUAN M, et al. Cell culture system for analysis of genetic heterogeneity within hepatocellular carcinomas and response to pharmacologic agents[J]. Gastroenterology, 2017, 152(1): 232-242.e4.
[21]FURUTA M, UENO M, FUJIMOTO A, et al. Whole genome sequencing discriminates hepatocellular carcinoma with intrahepatic metastasis from multi-centric tumors[J]. J Hepatol, 2017, 66(2): 363-373.
[22]ZHAI W, LIM TK, ZHANG T, et al. The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma[J]. Nat Commun, 2017, 8: 4565.
[23]XU LX, HE MH, DAI ZH, et al. Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma[J]. Ann Oncol, 2019, 30(6): 990-997.
[24]HUANG M, HE M, GUO Y, et al. The influence of immune heterogeneity on the effectiveness of immune checkpoint inhibitors in multifocal hepatocellular carcinomas[J]. Clin Cancer Res, 2020, 26(18): 4947-4957.
[25]SIA D, JIAO Y, MARTINEZ-QUETGLAS I, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features[J]. Gastroenterology, 2017, 153(3): 812-826.
[26]DUAN M, HAO J, CUI S, et al. Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing[J]. Cell Res, 2018, 28(3): 359-373.
[27]BAFFY G. Decoding multifocal hepatocellular carcinoma: An opportune pursuit[J]. Hepatobiliary Surg Nutr, 2015, 4(3): 206-210.
[28]MORIMOTO O, NAGANO H, SAKON M, et al. Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas[J]. J Hepatol, 2003, 39(2): 215-221.
[29]YAMAMOTO T, KAJINO K, KUDO M, et al. Determination of the clonal origin of multiple human hepatocellular carcinomas by cloning and polymerase chain reaction of the integrated hepatitis B virus DNA[J]. Hepatology, 1999, 29(5): 1446-1452.
[30]KAWAI S, IMAZEKI F, YOKOSUKA O, et al. Clonality in hepatocellular carcinoma: Analysis of methylation pattern of polymorphic X-chromosome-linked phosphoglycerate kinase gene in females[J]. Hepatology, 1995, 22(1): 112-117.
[31]MIAO R, LUO H, ZHOU H, et al. Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis[J]. J Hepatol, 2014, 61(4): 840-849.
[32]ZHANG Q, LOU Y, YANG J, et al. Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas[J]. Gut, 2019, 68(11): 2019-2031.
[33]XUE R, LI R, GUO H, et al. Variable intra-tumor genomic heterogeneity of multiple lesions in patients with hepatocellular carcinoma[J]. Gastroenterology, 2016, 150(4): 998-1008.
[34]CHEN XP, LONG X, JIA WL, et al. Viral integration drives multifocal HCC during the occult HBV infection[J]. J Exp Clin Cancer Res, 2019, 38(1): 261.
[35]AMIROUCHENE-ANGELOZZI N, SWANTON C, BARDELLI A. Tumor evolution as a therapeutic target[J]. Cancer Discov, 2017. [Online ahead of print]
[36]FALTAS BM, PRANDI D, TAGAWA ST, et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma[J]. Nat Genet, 2016, 48(12): 1490-1499.
[37]WANG J, CAZZATO E, LADEWIG E, et al. Clonal evolution of glioblastoma under therapy[J]. Nat Genet, 2016, 48(7): 768-776.
[38]LEE JK, WANG J, SA JK, et al. Spatiotemporal genomic architecture informs precision oncology in glioblastoma[J]. Nat Genet, 2017, 49(4): 594-599.
[39]SCHULZE K, NAULT JC, VILLANUEVA A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing[J]. J Hepatol, 2016, 65(5): 1031-1042.
[40]Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma[J]. Cell, 2017, 169(7): 1327-1341.e23.
[41]DING X, HE M, CHAN A, et al. Genomic and epigenomic features of primary and recurrent hepatocellular carcinomas[J]. Gastroenterology, 2020. [Online ahead of print]